GSK win for Euro RSCG Life MSC

pharmafile | July 7, 2005 | News story | Medical Communications  

GlaxoSmithKline has awarded the pan-European launch of a major new neurological product to Euro RSCG Life MSC, following a three-way pitch.

Euro RSCG Life MSC strategy director Mark Boulding said: "GlaxoSmithKline have already deployed a pan-European campaign we developed in 2004, and this additional business underlines how the closely integrated Euro RSCG Life global network can create highly impactful creative solutions which work internationally."

GSK's drug discovery efforts in neurology are led by the Neurology and Gastrointestinal Centre of Excellence for Drug Discovery which is based in Harlow, UK.

Its most recently approved products in the therapy area are ReQuip for restless legs syndrome and depression treatment Wellbutrin XL.

The pharma company is already a regular, major client of the Richmond-based agency, which has handled communications work for several of their brands.

The new campaign will see Euro RSCG Life undertake the complete scope of promotional communications.

A pan-European approach to launch activities is becoming more and common amongst pharmaceutical companies according to Boulding, who said his company was being asked to undertake an increasing amount of work on this basis.

Euro RSCG has offices dedicated to healthcare in all the major European markets and representation in just about every other market across Europe.

Related articles:

FDA approves Requip for restless legs syndrome 

Thursday , May 12, 2005

 

Related Content

No items found

Latest content